Renal function at two years in liver transplant patients receiving everolimus: Results of a randomized, multicenter study

American Journal of Transplantation

Volumn 13, Issue 7, 2013, Pages 1734-1745

  Saliba, F ^a   De Simone, P ^b   Nevens, F ^c   De Carlis, L ^d   Metselaar, H J ^e   Beckebaum, S ^f,g   Jonas, S ^h   Sudan, D ⁱ   Fischer, L ^j   Duvoux, C ^k   Chavin, K D ^l   Koneru, B ^m   Huang, M A ⁿ   Chapman, W C ^o   Foltys, D ^p   Dong, G ^q   Lopez, P M ^q   Fung, J ^r   Junge, G ^q  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^h UNIVERSITY HOSPITAL LEIPZIG   (Germany)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^k HENRI MONDOR HOSPITAL   (France)

^l MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^m RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

ⁿ HENRY FORD HOSPITAL   (United States)

^o WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p JOHANNES GUTENBERG UNIVERSITY   (Germany)

^q NOVARTIS PHARMA AG   (Switzerland)

^r LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

Everolimus; glomerular filtration rate; mTOR inhibitors; renal function; tacrolimus

Indexed keywords

CREATININE; CYSTATIN C; EVEROLIMUS; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; ASCITES; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIGESTIVE SYSTEM ULCER; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; ESTIMATED GLOMERULUS FILTRATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HYPERLIPIDEMIA; INCISIONAL HERNIA; INFECTION RATE; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NEPHROTIC SYNDROME; NEUTROPENIA; OPEN STUDY; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATED BIOPSY PROVEN ACUTE REJECTION; WOUND HEALING IMPAIRMENT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NORTH AMERICA; PROSPECTIVE STUDIES; SIROLIMUS; SOUTH AMERICA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879551497     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12280     Document Type: Article

References (23)

1. Tedesco Silva H Jr., Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10: 1401-1413.
2. Flechner SM, Kobashigawa J, Klintmalm G., Calcineurin inhibitor-sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1-15.
3. De Simone P, Metselaar HJ, Fischer L, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trial. Liver Transpl 2009; 15: 1262-1269.
4. Saliba F, Dharancy S, Lorho R, et al. Conversion to everolimus in maintenance liver transplant patients: A multicenter, retrospective analysis. Liver Transpl 2011; 17: 905-913.
5. Masetti M, Montalti R, Rompianesi G, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 2010; 10: 2252-2262.
6. Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT. Am J Transplant 2012; 12: 1855-1865.
7. De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: A randomized controlled trial. Am J Transplant 2012; 12: 3008-3020.
8. Poggio ED, Wang X, Weinstein DM, et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006; 6: 100-108.
9. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997; 25: 658-663.
10. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
11. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
12. Shetty K, Timmins K, Brensinger C, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004; 10: 911-918.
13. Burra P, Senzolo M, Masier A, et al. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study. Dig Liver Dis 2009; 41: 350-356.
14. Herlenius G, Fistouris J, Olausson M, Felldin M, Bäckman L, Friman S., Early renal function post-liver transplantation is predictive of progressive chronic kidney disease. Scand J Gastroenterol 2008; 43: 344-349.
15. O'Riordan A, Wong V, McCormick PA, Hegarty JE, Watson AJ., Chronic kidney disease post-liver transplantation. Nephrol Dial Transplant 2006; 21: 2630-2636.
16. Albano L, Berthoux F, Moal MC, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009; 88: 69-76.
17. Wadei HM, Zaky ZS, Keaveny AP, et al. Proteinuria following sirolimus conversion is associated with deterioration of kidney function in liver transplant recipients. Transplantation 2012; 93: 1006-1012.
18. Lebranchu Y, Thierry A, Thervet E, et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am J Transplant 2011; 11: 1665-1675.
19. Sánchez-Fructuoso AI, Ruiz JC, Calvo N, et al. Everolimus as primary immunosuppression in kidney transplantation: Experience in conversion from calcineurin inhibitors. Transplantation 2012; 93: 398-405.
20. Lee JP, Heo NJ, Joo KW, et al. Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function. Nephrol Dial Transplant 2010; 25: 2772-2785.
21. Fabrizi F, Dixit V, Martin P, Messa P., Chronic kidney disease after liver transplantation: Recent evidence. Int J Artif Organs 2010; 33: 803-811.
22. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB., Estimation of glomerular filtration rates before and after orthotopic liver transplantation: Evaluation of current equations. Liver Transpl 2004; 10: 301-309.
23. Cantarovich M, Yoshida EM, Peltekian KM, et al. Poor prediction of the glomerular filtration rate using current formulas in de novo liver transplant patients. Transplantation 2006; 82: 433-436.